Sun Pharma Announces 5-Year Sustained Efficacy and Safety Results for ILUMYA (tildrakizumab-asmn) in…
ILUMYA is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in…